Sio Gene Therapies Inc. Common Stock
SIOX
SIOX was delisted on the 22nd of March, 2023.
56 hedge funds and large institutions have $54.4M invested in Sio Gene Therapies Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 13 increasing their positions, 13 reducing their positions, and 19 closing their positions.
37% more capital invested
Capital invested by funds: $39.7M → $54.4M (+$14.7M)
0% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 13
10% less funds holding
Funds holding: 62 → 56 (-6)
32% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 19
37% less call options, than puts
Call options by funds: $383K | Put options by funds: $604K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Suvretta Capital Management
New York
|
+$15.5M |
| 2 |
Two Sigma Investments
New York
|
+$1.55M |
| 3 |
Renaissance Technologies
New York
|
+$1.36M |
| 4 |
Two Sigma Advisers
New York
|
+$915K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$900K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sio Capital Management
New York
|
-$1.21M |
| 2 |
SCA
Sassicaia Capital Advisers
Jericho,
New York
|
-$863K |
| 3 |
Morgan Stanley
New York
|
-$839K |
| 4 |
AAA
Affinity Asset Advisors
New York
|
-$695K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$586K |
SIOX Hedge Fund Activity: Q1 2021 in Review
56 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Sio Gene Therapies Inc. Common Stock (SIOX) for Q1 2021, worth a combined $54.4M — up 37% from $39.7M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of SIOX and 13 opened new positions — a net loss of 6 holders — while 13 trimmed existing stakes and 13 added.
The largest buyer was Suvretta Capital Management, opening a new position worth an estimated $15.5M. The largest seller was Sio Capital Management, cutting an estimated $1.21M.
- 56 institutional investors held Sio Gene Therapies Inc. Common Stock (SIOX) as of Q1 2021, down from 62 in Q4 2020.
- Funds reported $54.4M of Sio Gene Therapies Inc. Common Stock stock for Q1 2021, up 37% quarter-over-quarter.
- 13 funds opened new Sio Gene Therapies Inc. Common Stock positions in Q1 2021 and 19 closed out, a net change of -6 holders.
- The largest Sio Gene Therapies Inc. Common Stock buyer in Q1 2021 was Suvretta Capital Management, an estimated $15.5M added.
- The largest Sio Gene Therapies Inc. Common Stock seller in Q1 2021 was Sio Capital Management, an estimated $1.21M sold.
Based on aggregated 13F filings for Q1 2021.